Skip to content
healthcare.dev
Get a free key

Blowfish

NDC 75920-0464, Aspirin, Caffeine, tablet, effervescent, from Rally Labs LLC.

Product NDC
75920-0464
Status
Listed
Labeler
Rally Labs LLC
Dosage form
TABLET, EFFERVESCENT
Route
ORAL
Product type
HUMAN OTC DRUG
Marketing category
OTC MONOGRAPH DRUG
Application
M013
DEA schedule
None
Request
curl https://api.healthcare.dev/v1/drugs/ndc/75920-0464 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • ASPIRIN500 mg/1
  • CAFFEINE60 mg/1

Pharmacologic classes

Anti-Inflammatory Agents, Non-Steroidal [CS]; Central Nervous System Stimulant [EPC]; Central Nervous System Stimulation [PE]; Cyclooxygenase Inhibitors [MoA]; Decreased Platelet Aggregation [PE]; Decreased Prostaglandin Production [PE]; Methylxanthine [EPC]; Nonsteroidal Anti-inflammatory Drug [EPC]; Platelet Aggregation Inhibitor [EPC]; Xanthines [CS]

Package NDCNDC-11Package
75920-0464-1759200464012 TABLET, EFFERVESCENT in 1 BOX (75920-0464-1)
75920-0464-27592004640220 TABLET, EFFERVESCENT in 1 BAG (75920-0464-2)
75920-0464-47592004640440 TABLET, EFFERVESCENT in 1 BAG (75920-0464-4)
75920-0464-57592004640520 TABLET, EFFERVESCENT in 1 BOX (75920-0464-5)
75920-0464-6759200464064 TABLET, EFFERVESCENT in 1 BOX (75920-0464-6)
75920-0464-77592004640720 TABLET, EFFERVESCENT in 1 BOX (75920-0464-7)
75920-0464-87592004640812 TABLET, EFFERVESCENT in 1 BOX (75920-0464-8)

Linked data

RxNorm, label and prices

RxNorm concepts

RxNorm links no concept to this product's packages.

Related lookups

No FDA label, Medicare Part B payment limit or NADAC price is linked to this product.

Use it

Look up 75920-0464 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/75920-0464 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 75920-0464. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Get a free keyNDC docsConnect the MCP server

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.